COVID-19 Information

Edit Entry | Edit CV

Todd W Miller, PhD

Title(s):
Associate Professor of Molecular and Systems Biology

Additional Titles/Positions/Affiliations:
Director, PhD Program in Experimental & Molecular Medicine
Co-Director, Cancer Biology & Therapeutics Research Program, Norris Cotton Cancer Center
Scientific Director, Comprehensive Breast Program, Norris Cotton Cancer Center
Co-Director, Molecular Tumor Board, Norris Cotton Cancer Center

Department(s):
Molecular and Systems Biology

Education:
University of Connecticut (Storrs, CT), B.S., Physiology & Neurobiology, 1998
University at Albany (Albany, NY), Ph.D. in Biomedical Sciences, 2004
Vanderbilt University (Nashville, TN), Post-doctoral Fellowship in Breast Cancer, 2004-2009

Programs:
Program in Experimental and Molecular Medicine

Websites:
Lab website:
https://geiselmed.dartmouth.edu/miller/

Publications:
http://www.ncbi.nlm.nih.gov/sites/myncbi/todd.miller.1/bibliography/42064063/public/?sort=date&direction=descending

Contact Information:

1 Medical Center Drive
Rubin Bldg, HB 7936
Lebanon NH 03756

Office: Rubin 604
Phone: 603-653-9284
Fax: 603-653-9952
Email: Todd.W.Miller@Dartmouth.edu


Professional Interests:

Breast cancer, targeted therapeutics, signaling pathways, drug resistance, biomarker development

Grant Information:

R01 CA200994 (PI: Miller) 04/01/2017 – 03/31/2022
NIH/NCI
A precision medicine basis for estrogen therapy for advanced breast cancer.

R01 CA211869 (PI: Miller)
09/04/2017 – 08/31/2022
NIH/NCI
A precision medicine basis for Pl3K inhibition in ER+ breast cancer.

Pilot Project Grant (PI: Miller) 08/01/2014 – no end
Norris Cotton Cancer Center Early-Phase Trials Program
Alternating estradiol and anti-estrogen therapies to prevent disease progression in advanced ER+/HER2- breast cancer.

Investigator-initiated Phase I clinical study (PI: Schwartz)
Takeda Pharmaceuticals 10/01/2015 – no end
Phase 1 study of combination of MLN9708 and Fulvestrant in patients with advanced ER+ breast cancer.

Courses Taught:

PEMM 102- Scientific Basis of Disease II
PEMM 126- Cancer Biology
PEMM 132- Clinical Management of Cancer

Biography:

Dr. Miller received his B.S. in Physiology and Neurobiology at the University of Connecticut in 1998, and his Ph.D. in Biomedical Sciences at the State University of New York at Albany in 2004 (thesis: Immunization and single-chain Fv intrabody gene therapies for Huntington’s Disease). He did his postdoctoral training at Vanderbilt University (2004-2009), and served as a Research Faculty member 2009-2012. Dr. Miller joined the Geisel School of Medicine at Dartmouth in 2012.

Mentoring Information:

2012-2014 Lloye Dillon, Ph.D., Postdoctoral Fellow (Current Position: Senior Scientist, Research & Development, OncoTAb, Inc., Charlotte, NC)
2012-2018 Wei Yang, M.S., PhD Student (Current position: Postdoctoral Fellow at Memorial Sloan Kettering Cancer Center)
2013-2018 Sarah Hosford, PhD Student (Current position: Scientist in In Vivo Pharmacology at Cobalt Biomedicine)
2014-2018 Kevin Shee, MD/PhD student (Current position: medical student at Geisel)
2015-present Riley Hampsch, PhD student
2016-present Nicole Traphagen, PhD student
2017-present Jason Wells, PhD student
2017-present Bianca Romo, PhD student
2018-present Jackie Griffin, PhD, Postdoctoral Fellow


Selected Publications:

 

Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer.
Axelrod ML, Nixon MJ, Gonzalez-Ericsson PI, Bergman RE, Pilkinton MA, McDonnell WJ, Sanchez V, Opalenik SR, Loi S, Zhou J, Mackay S, Rexer BN, Abramson VG, Jansen VM, Mallal S, Donaldson J, Tolaney SM, Krop IE, Garrido-Castro AC, Marotti JD, Shee K, Miller TW, Sanders ME, Mayer IA, Salgado R, Balko JM
Clin Cancer Res. 2020 Aug 21; doi: 10.1158/1078-0432.CCR-19-3685. Epub 2020 Aug 21.
PMID: 32826327

Identification of let-7f-5p as a novel biomarker of recurrence in non-muscle invasive bladder cancer.
Shee K, Seigne JD, Karagas MR, Marsit CJ, Hinds JW, Schned AR, Pettus JR, Armstrong DA, Miller TW, Andrew AS
Cancer Biomark. 2020 Jun 28; doi: 10.3233/CBM-191322. Epub 2020 Jun 28.
PMID: 32623385

Molecular matching and treatment strategies for advanced stage lung cancer at Dartmouth-Hitchcock Medical Center: A three-year review of a Molecular Tumor Board.
Bernhardt EB, Chamberlin MD, Gorlov IP, de Abreu FB, Bloch KJ, Peterson JD, Tsongalis GJ, Shirai K, Dragnev KH, Miller TW, Tafe LJ
Pract Lab Med. 2020 Aug;21:e00174. doi: 10.1016/j.plabm.2020.e00174. Epub 2020 Jun 12.
PMID: 32613070

Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer.
Chamberlin MD, Wells JD, Shee K, Bean JR, Marotti JD, Wells WA, Trask HW, Kolling FW, Bhatt A, Kaufman PA, Schwartz GN, Gemery JM, McNulty NJ, Tsapakos MJ, Barth RJ, Arrick BA, Gui J, Miller TW
Breast Cancer Res Treat. 2020 Aug;182(3):665-677. doi: 10.1007/s10549-020-05714-2. Epub 2020 Jun 19.
PMID: 32562118

AMPK Activation by Metformin Promotes Survival of Dormant ER+ Breast Cancer Cells.
Hampsch RA, Wells JD, Traphagen NA, McCleery CF, Fields JL, Shee K, Dillon LM, Pooler DB, Lewis LD, Demidenko E, Huang YH, Marotti JD, Goen AE, Kinlaw WB, Miller TW
Clin Cancer Res. 2020 Jul 15;26(14):3707-3719. doi: 10.1158/1078-0432.CCR-20-0269. Epub 2020 Apr 22.
PMID: 32321715

Endocytosis of very low-density lipoproteins: an unexpected mechanism for lipid acquisition by breast cancer cells.
Lupien LE, Bloch K, Dehairs J, Traphagen NA, Feng WW, Davis WL, Dennis T, Swinnen JV, Wells WA, Smits NC, Kuemmerle NB, Miller TW, Kinlaw WB
J Lipid Res. 2020 Feb;61(2):205-218. doi: 10.1194/jlr.RA119000327. Epub 2019 Dec 5.
PMID: 31806729

Statistical determination of synergy based on Bliss definition of drugs independence.
Demidenko E, Miller TW
PLoS One. 2019;14(11):e0224137. doi: 10.1371/journal.pone.0224137. Epub 2019 Nov 25.
PMID: 31765385

Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy.
Shee K, Wells JD, Jiang A, Miller TW
PLoS One. 2019;14(11):e0224267. doi: 10.1371/journal.pone.0224267. Epub 2019 Nov 4.
PMID: 31682620

A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition.
Shee K, Wells JD, Ung M, Hampsch RA, Traphagen NA, Yang W, Liu SC, Zeldenrust MA, Wang L, Kalari KR, Yu J, Boughey JC, Demidenko E, Kettenbach AN, Cheng C, Goetz MP, Miller TW
Clin Cancer Res. 2020 Jan 1;26(1):159-170. doi: 10.1158/1078-0432.CCR-18-2213. Epub 2019 Sep 26.
PMID: 31558472

Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma.
Miller TW, Traphagen NA, Li J, Lewis LD, Lopes B, Asthagiri A, Loomba J, De Jong J, Schiff D, Patel SH, Purow BW, Fadul CE
J Neurooncol. 2019 Sep;144(3):563-572. doi: 10.1007/s11060-019-03258-0. Epub 2019 Aug 9.
PMID: 31399936

View more publications on PubMed